Literature DB >> 27890820

Recent developments in natural product-based drug discovery for tuberculosis.

Maryline Dong1, Bernhard Pfeiffer1, Karl-Heinz Altmann2.   

Abstract

Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB). Although the current clinical TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb). This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb. These compounds could help to replenish the dry clinical TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27890820     DOI: 10.1016/j.drudis.2016.11.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

Review 1.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 2.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

3.  Characterization of Pyridomycin B Reveals the Formation of Functional Groups in Antimycobacterial Pyridomycin.

Authors:  Tingting Huang; Zihua Zhou; Maolong Wei; Lin Chen; Zhihong Xiao; Zixin Deng; Shuangjun Lin
Journal:  Appl Environ Microbiol       Date:  2022-02-02       Impact factor: 5.005

Review 4.  Protein-protein interactions in bacteria: a promising and challenging avenue towards the discovery of new antibiotics.

Authors:  Laura Carro
Journal:  Beilstein J Org Chem       Date:  2018-11-21       Impact factor: 2.883

5.  Antimycobacterial, Enzyme Inhibition, and Molecular Interaction Studies of Psoromic Acid in Mycobacterium tuberculosis: Efficacy and Safety Investigations.

Authors:  Sherif T S Hassan; Miroslava Šudomová; Kateřina Berchová-Bímová; Shanmugaraj Gowrishankar; Kannan R R Rengasamy
Journal:  J Clin Med       Date:  2018-08-20       Impact factor: 4.241

Review 6.  Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.

Authors:  Ashley L Biecker; Xiaodong Liu; Jon S Thorson; Zhaoyong Yang; Steven G Van Lanen
Journal:  Molecules       Date:  2019-01-25       Impact factor: 4.411

7.  A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases.

Authors:  Miroslava Šudomová; Mohammad Ali Shariati; Javier Echeverría; Ioana Berindan-Neagoe; Seyed Mohammad Nabavi; Sherif T S Hassan
Journal:  Mar Drugs       Date:  2019-11-14       Impact factor: 5.118

Review 8.  Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.

Authors:  Saad Alghamdi; Shaheed Ur Rehman; Nashwa Talaat Shesha; Hani Faidah; Muhammad Khurram; Sabi Ur Rehman
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

Review 9.  Schweinfurthins A-Q: isolation, synthesis, and biochemical properties.

Authors:  Dipesh S Harmalkar; Jyotirling R Mali; Aneesh Sivaraman; Yongseok Choi; Kyeong Lee
Journal:  RSC Adv       Date:  2018-06-08       Impact factor: 4.036

10.  Identification of potent chromone embedded [1,2,3]-triazoles as novel anti-tubercular agents.

Authors:  Viswanadh Nalla; Aslam Shaikh; Sanket Bapat; Renu Vyas; M Karthikeyan; P Yogeeswari; D Sriram; M Muthukrishnan
Journal:  R Soc Open Sci       Date:  2018-04-04       Impact factor: 2.963

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.